CClinicalTrials.gg
Not yet recruitingNCT07720037Updated Sep 29, 2026

Efficacy Comparison of 10-Day High-Dose Versus 14-Day Standard-Dose Vonoprazan Plus Amoxicillin in Helicobacter Pylori Eradication: A Multicenter Non-Inferiority Randomized Controlled Trial

A Phase 4 interventional study of 10-day group and 14-day group in Helicobacter Infection, Vonoprazan and Amoxicillin, sponsored by Shandong University. Not yet recruiting. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-09-29.

Sponsored by Shandong University · Phase 4, Interventional, and Treatment

Phase
Phase 4
Study type
Interventional
Enrollment
232
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Study summary

This is a multicenter non-inferiority randomized controlled trial for patients infected with Helicobacter pylori. Eligible participants will be randomly split into two groups. One group will take high-dose vonoprazan combined with amoxicillin (vonoprazan 20mg tid, amoxicillin 1000mg bid) for 10 days, while the other group will receive standard-dose vonoprazan plus amoxicillin (vonoprazan 20mg bid, amoxicillin 1000mg bid) for 14 days. The main goal of this study is to compare how well the two treatment plans clear the H. pylori bacteria. We aim to check if the 10-day high-dose treatment works no worse than the 14-day standard treatment. Every participant will take a follow-up test after treatment to see if the bacteria have been eliminated.

02

Conditions studied

  • Helicobacter Infection
  • Vonoprazan
  • Amoxicillin
03

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  1. Aged 18 to 70 years, no restriction on gender
  2. Current Helicobacter pylori infection (positive result of either ¹³C or ¹⁴C urea breath test)
  3. No prior history of Helicobacter pylori eradication therapy

Exclusion criteria

Exclusion Criteria:

  1. Severe underlying diseases, including hepatic insufficiency, renal insufficiency, malignant tumors, etc.
  2. Active gastrointestinal bleeding
  3. History of upper gastrointestinal surgery
  4. History of allergy to study medications
  5. Use of bismuth agents or antibiotics within 4 weeks prior to enrollment; use of acid-suppressive agents within 2 weeks prior to enrollment
  6. Pregnant or breastfeeding women, and subjects who refuse to take contraceptive measures during the trial
  7. Behaviors that may increase disease risks, such as chronic alcohol abuse and drug addiction
  8. Subjects who are unable or unwilling to sign the informed consent form
04

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
232 participants (estimated)

Study arms

  • Experimental
    10-day group

    10-day dual therapy, vonoprazan (Takeda Pharmaceutical Company Limited) 20mg tid, amoxicillin (United Laboratories Co., LTD) 1000mg tid

    Drug: 10-day group

  • Active comparator
    14-day group

    14-day dual therapy, vonoprazan (Takeda Pharmaceutical Company Limited) 20mg bid, amoxicillin (United Laboratories Co., LTD) 1000mg tid

    Drug: 14-day group

Interventions

  • Drug10-day group

    vonoprazan 20mg tid and amoxicillin 1000mg tid for 10 days

  • Drug14-day group

    vonoprazan 20mg bid and amoxicillin 1000mg tid for 14 days

05

What researchers measure

Primary outcomes

  1. Eradication rates

    Both intention to treat (ITT) and per-protocol (PP) analyses will be used for the assessment of the eradication rates of Helicobacter pylori in two groups. The ITT analysis includes all randomly assigned patients who take at least one dose of the study medicines. The PP analysis is limited to patients who take over 90% of the study medications and complete follow-up.

    Time frame: immediately after the procedure

Secondary outcomes

  1. Rate of adverse reactions

    Time frame: immediately after the procedure

  2. Patient compliance

    Good compliance is defined as the actual dosage is within the range of 80%-100% of the dosage that should be taken.

    Time frame: immediately after the procedure

06

Study locations

No study locations are listed for this record.

07

Registry details

Key details

Study ID
NCT07720037
Lead sponsor
Shandong University
Responsible party
Xiuli Zuo (Director of Qilu Hospital gastroenterology department, Shandong University) — Principal investigator
First posted
Jul 22, 2026
Start date
Sep 30, 2026 (estimated)
Primary completion
Sep 30, 2026 (estimated)
Completion
May 30, 2028 (estimated)
Last update
Sep 29, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion